Holen Sie sich die Stockscreener-App
198.02
0.17%
0.33
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$197.69
Offen:
$196.66
24-Stunden-Volumen:
519.92K
Relative Volume:
0.54
Marktkapitalisierung:
$21.76B
Einnahmen:
$11.04B
Nettoeinkommen (Verlust:
$1.04B
KGV:
22.60
EPS:
8.7626
Netto-Cashflow:
$1.36B
1W Leistung:
-0.07%
1M Leistung:
-5.82%
6M Leistung:
+9.43%
1J Leistung:
+17.90%
1-Tages-Spanne:
$196.06
$199.14
1-Wochen-Bereich:
$192.73
$199.14
52-Wochen-Spanne:
$157.20
$213.50
Quest Diagnostics Inc Stock (DGX) Company Profile
Firmenname
Quest Diagnostics Inc
Sektor
Branche
Telefon
(973) 520-2700
Adresse
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
198.02 | 21.76B | 11.04B | 1.04B | 1.36B | 8.7626 |
TMO
Thermo Fisher Scientific Inc
|
491.46 | 182.57B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
191.12 | 135.26B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
569.55 | 45.24B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
115.48 | 32.63B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
304.24 | 29.85B | 3.17B | 642.63M | 516.49M | 10.77 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-08-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-04-02 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-01-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | Jefferies | Buy |
| 2024-10-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Fortgesetzt | Evercore ISI | In-line |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-02-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2023-12-12 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-06-29 | Eingeleitet | Piper Sandler | Neutral |
| 2023-05-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-23 | Eingeleitet | Evercore ISI | In-line |
| 2022-11-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-23 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-02 | Herabstufung | Jefferies | Buy → Hold |
| 2022-01-28 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-03-12 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Hochstufung | Argus | Hold → Buy |
| 2020-07-29 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-09 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-04-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2019-04-02 | Hochstufung | Jefferies | Hold → Buy |
| 2019-03-18 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-01-31 | Herabstufung | Argus | Buy → Hold |
| 2019-01-17 | Eingeleitet | UBS | Neutral |
| 2019-01-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Quest Diagnostics Inc Aktie (DGX) Neueste Nachrichten
Drug Screening Market Trends 2026–2031: Chromatography and Mass Spectrometry Held a 44.77% Share in 2025 Amid Growing Demand for Advanced Testing, Reports Mordor Intelligence - GlobeNewswire Inc.
Quest Diagnostics (DGX) director defers pay into 198 phantom stock units - Stock Titan
Justices Pass On FCA Suit Alleging Quest Diagnostics Fraud - Law360
Eastern Bank Takes Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Assenagon Asset Management S.A. Buys 19,361 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Inc. stock outperforms competitors despite losses on the day - MarketWatch
Vanguard (DGX) amends 13G, reports 0 shares after Jan 12, 2026 realignment - Stock Titan
Quest Diagnostics Earnings Preview: What to Expect - Yahoo Finance
Quest Diagnostics Incorporated $DGX Shares Acquired by SG Americas Securities LLC - MarketBeat
DGX SEC FilingsQuest Diagnostics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Quest Diagnostics Incorporated (NYSE:DGX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Quest Diagnostics (DGX) down 4.2% since last earnings report: Can it rebound? - MSN
Union Bancaire Privee UBP SA Acquires 8,744 Shares in Quest Diagnostics - National Today
8,744 Shares in Quest Diagnostics Incorporated $DGX Acquired by Union Bancaire Privee UBP SA - MarketBeat
Paradiem LLC Buys New Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics to Report Q1 2026 Financial Results on April 21 - intellectia.ai
Quest Diagnostics to Release First Quarter Financial Results on April 21, 2026 - GuruFocus
Quest Diagnostics schedules April 21 earnings release, 8:30 a.m. call - Stock Titan
How Is Quest Diagnostics’ Stock Performance Compared to Other Healthcare Stocks? - Yahoo Finance
Davis Selected Advisers Acquires 7,192 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Zacks Industry Outlook Features Quest Diagnostics, DaVita, Option Care Health, and Addus HomeCare - Bitget
Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, Option Care Health and Addus HomeCare - Zacks Investment Research
Danica Pension Livsforsikringsaktieselskab Buys Shares of 70,846 Quest Diagnostics Incorporated $DGX - MarketBeat
Achmea Investment Management B.V. Grows Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
4 Outpatient Home Health Stocks Gaining Attention Amid Market Shifts - TradingView
Quest Diagnostics Incorporated $DGX Shares Sold by Chevy Chase Trust Holdings LLC - MarketBeat
Aquatic Capital Management LLC Has $8.06 Million Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
EdgePoint Investment Group Inc. Grows Position in Quest Diagnostics Incorporated $DGX - MarketBeat
CSM Advisors LLC Sells 20,078 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Crawford Investment Counsel Inc. Purchases 9,473 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated $DGX Stock Position Increased by 8 Knots Management LLC - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Sees Large Decrease in Short Interest - MarketBeat
iSAM Funds UK Ltd Invests $1.47 Million in Quest Diagnostics Incorporated $DGX - MarketBeat
Integral Health Asset Management LLC Sells 65,000 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Elects Wentworth to Board of Directors - New Jersey Business Magazine
Korea Investment CORP Sells 14,900 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Elects Timothy Wentworth, Former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to Board of Directors - Sahm
Quest Diagnostics adds ex-Walgreens CEO to board By Investing.com - Investing.com India
Quest Diagnostics Elects Timothy Wentworth to Board of Directors - citybiz.co
Quest Diagnostics Elects Former Walgreens Boots Alliance CEO Timothy Wentworth to Board of Directors - Minichart
Quest Diagnostics (DGX) Appoints Timothy Wentworth to Board of D - GuruFocus
Quest Diagnostics Elects Timothy Wentworth, Former CEO of Walgre - GuruFocus
Quest Diagnostics names Timothy Wentworth to board, joins Compensation and Quality Committees - TradingView
Quest Diagnostics adds ex-Walgreens CEO to board - Investing.com
Quest Diagnostics Elects Timothy Wentworth, Former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to Board of Directors – Company AnnouncementFT.com - markets.ft.com
Quest Diagnostics (DGX) Down 4.2% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Swiss National Bank Reduces Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Director at Quest Diagnostics (NYSE: DGX) gets 215 RSUs - Stock Titan
Quest Diagnostics (DGX) director Timothy Wentworth files insider Form 3 - Stock Titan
Quest Diagnostics Incorporated $DGX Position Trimmed by Schroder Investment Management Group - MarketBeat
Finanzdaten der Quest Diagnostics Inc-Aktie (DGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.36%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):